Xiao Taiwu, Zhang Li, Chen Lei, Liu Guozhen, Feng Zhenjun, Gao Lei
Department of Hematology, Liaocheng People's Hospital, 67 Dong Chang Xi Road, Liaocheng, 252000, Shandong Province, China,
Tumour Biol. 2014 Aug;35(8):7951-6. doi: 10.1007/s13277-014-2080-0. Epub 2014 May 16.
T cell immunoglobulin- and mucin-domain-containing molecule 3 (Tim-3) plays a critical role in immune tolerance by suppressing the activation and proliferation of T cells. The purpose of this study was to investigate the effect of Tim-3 on the development of diffuse large B cell lymphoma (DLBCL). A total of 40 newly diagnosed DLBCL patients and 30 healthy donors were recruited. Tim-3 expression on peripheral CD4+ T and CD8+ T cells was analyzed by flow cytometry. Data showed that expression of Tim-3 was significantly increased on both CD4+ and CD8+ T cells in DLBCL patients than in healthy controls (P < 0.001 and P < 0.001, respectively). Also, level of Tim-3 on CD4+ T cells was positively correlated with CD8+ T cells in patients (P < 0.001). Further analyses revealed that patients with advanced tumor stages had elevated Tim-3 expression on CD4+ and CD8+ T cells compared to those with primary tumor stages. In addition, levels of Tim-3 on CD4+ and CD8+ T cells were significantly elevated in DLBCL patients with bone marrow involvement or B symptoms. Our results suggest that Tim-3 is involved in the development of DLBCL.
含T细胞免疫球蛋白和粘蛋白结构域分子3（Tim-3）通过抑制T细胞的活化和增殖在免疫耐受中发挥关键作用。本研究旨在探讨Tim-3对弥漫性大B细胞淋巴瘤（DLBCL）发生发展的影响。共招募了40例新诊断的DLBCL患者和30名健康供者。采用流式细胞术分析外周血CD4+T细胞和CD8+T细胞上Tim-3的表达。数据显示，与健康对照相比，DLBCL患者CD4+和CD8+T细胞上Tim-3的表达均显著增加（分别为P＜0.001和P＜0.001）。此外，患者CD4+T细胞上Tim-3水平与CD8+T细胞呈正相关（P＜0.001）。进一步分析显示，与原发性肿瘤分期患者相比，晚期肿瘤分期患者CD4+和CD8+T细胞上Tim-3表达升高。此外，骨髓受累或有B症状的DLBCL患者CD4+和CD8+T细胞上Tim-3水平显著升高。我们的结果表明，Tim-3参与了DLBCL的发生发展。
